4D Mol­e­c­u­lar Ther­a­peu­tic­s' gene ther­a­py cuts Eylea use in wet AMD pa­tients, biotech di­vulges plans for piv­otal stud­ies

4D Mol­e­c­u­lar Ther­a­peu­tics said peo­ple with wet age-re­lat­ed mac­u­lar de­gen­er­a­tion (AMD) who re­ceived the com­pa­ny’s gene ther­a­py as part of a clin­i­cal tri­al need­ed few­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER